No two patients feel pain the same way.
So why would their therapy be treated the same?

One of the most important lessons I’ve learned in this space is just how dramatically a patient’s experience can change when they’re partnered with the right clinician and the right technology.

This week, I was reminded of that while reviewing a patient story published in Psychology Today; about a patient of Robert Moghim, M.D. and exactly why EVOKE® is fundamentally different.

A patient implanted in February 2024 returned nearly 10 months later and shared that her results didn’t feel quite as “magical” as they once had. That’s expected. As the epidural space evolves and medications change, therapy must adapt. The first 3–6 months are all about fine-tuning, and I was so grateful we had the opportunity to reconnect and do exactly that.

EVOKE® doesn’t guess. It listens.
By sensing ECAPs, the system delivers truly objective therapy and automatically adjusts dosing more than 4 million times per day, maintaining consistent spinal cord stimulation despite changes in movement, posture, and breathing.

The EVOKE® Study shows that 83% of patients experience durable pain relief out to three years.

Because long-term outcomes matter.
And so does how we care for patients, long after implant.